Skip to main content

Table 1 Patient characteristics at the time of second-line chemotherapy

From: A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

 

No. of patients (n = 725)

Median age (range), years

56 (22–86)

Male gender

473 (65%)

Prior therapy

 

   Surgery

364 (50%)

   Adjuvant chemotherapy ± radiotherapy

145 (20%)

First-line chemotherapy*

 

   FP (± leucovorin) or XP

402 (56%)

   ECF or ECX

29 (4%)

   Taxane (paclitaxel or docetaxel) + cisplatin

252 (35%)

   Irinotecan- or oxaliplatin-based

42 (6%)

Response to first-line chemotherapy

 

   Responder

143 (20%)

   Non-responder or unknown

582 (80%)

Treatment-free interval, months

 

   Median (range)

2 (1–26)

ECOG performance status

 

   0–1

586 (81%)

   2 or more

139 (19%)

Involved site(s)

 

   Two or more involved sites

283 (39%)

   Ascites

193

   Liver metastasis

139

   Bone marrow involvement (n = 69)

41

Baseline laboratory parameters, median

 

   Hemoglobin, g/l

9.8

   Albumin, g/dl

3.4

   Alkaline phosphatase, U/l

86

   Bilirubin, mg/dl

0.5

   Calcium, mg/dl

8.9

  1. *FP, 5-fluorouracil + cisplatin; XP; capecitabine + cisplatin; ECF, epirubicin + cisplatin + 5-fluorouracil; ECX, epirubicin + cisplatin + capecitabine; ECOG, Eastern Cooperative Oncology Group.